Advertisement
Australia markets open in 4 hours 30 minutes
  • ALL ORDS

    7,937.90
    +35.90 (+0.45%)
     
  • AUD/USD

    0.6487
    +0.0036 (+0.56%)
     
  • ASX 200

    7,683.50
    +34.30 (+0.45%)
     
  • OIL

    83.37
    +1.47 (+1.79%)
     
  • GOLD

    2,338.30
    -8.10 (-0.35%)
     
  • Bitcoin AUD

    102,675.58
    +445.02 (+0.44%)
     
  • CMC Crypto 200

    1,435.28
    +20.52 (+1.45%)
     

Midday movers: Home Depot, Capital One Financial, Tesla and more

Investing.com -- Stocks were mixed at midday Tuesday as investors waited for clarity on the direction of negotiations over raising the debt ceiling, with a June 1 deadline just weeks away. Here are the market movers for May 16.

Home Depot Inc (NYSE:HD) shares fell 1.4% after the home improvement retailer reported weaker-than-expected sales for the first quarter and lowered its outlook for the year as shoppers cut down on spending. Same-store sales fell 4.5%. Capital One Financial Corporation (NYSE:COF) shares rose 2.4% after Warren Buffett's Berkshire Hathaway (NYSE:BRKa) disclosed it had taken on a new 9.9 million share position in the card company as of the end of the first quarter. Tesla Inc (NASDAQ:TSLA) shares were up 1.3% in anticipation of the electric vehicle maker's annual shareholder meeting this afternoon. Earlier, billionaire George Soros' fund disclosed it no longer had a stake in the company. Horizon Therapeutics PLC (NASDAQ:HZNP) shares were falling 15% after the Federal Trade Commission sued to block its $28 billion acquisition by pharma company Amgen Inc (NASDAQ:AMGN).

Newell Brands Inc (NASDAQ:NWL) shares fell 3.6% after the maker of Rubbermaid and other household products cut its dividend by 70%. Last month, Newell disappointed with a wider-than-expected loss in the first quarter and a below-forecast second-quarter profit projection.

Related Articles

ADVERTISEMENT

Midday movers: Home Depot, Capital One Financial, Tesla and more

Bridgewater dumps bank stocks amid turmoil in first quarter -filings

US FTC sues to block Amgen's $27.8 billion deal for Horizon Therapeutics